The Asia Pacific Insulin Pump Market should witness market growth of 11.0% CAGR during the forecast period (2023-2030).
One of the most dynamic areas of healthcare is the care for people with diabetes, which is undergoing several changes. The technique for continuously delivering subcutaneous insulin is one of the cutting-edge technologies. The market is altering how people with diabetes are treated and managed. Additionally, ongoing technology development is opening up new possibilities for the treatment of diabetes, which is anticipated to lead to a high adoption rate in the coming years. The needs of people with type 1 diabetes are met by the goods that have been introduced to the market. There is very little use of insulin pumps among people with type II diabetes.
New potential for the expansion of the market has been created by the boom in published studies concerning the closed-loop system with insulin pumps in the management of diabetes. In the near future, several hybrid systems related to insulin delivery are anticipated to become commercially available. Numerous systems are anticipated to come along with those already on the market.
The WHO reports that China's population is growing older at one of the quickest rates in the countries. By 2040, 28% of China's population is anticipated to be older than 60 due to increased life expectancy and declining birth rates. The aging population is predicted to be more prone to developing a range of illnesses; therefore, it is expected that the prevalence of diseases like cancer, diabetes, and others will increase along with it. Due to all of these considerations, market players operating in the regional nations should have significant growth prospects.
The China market dominated the Asia Pacific Insulin Pump Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $670.8 million by 2030. The Japan market is poised to grow at a CAGR of 10.3% during (2023-2030). Additionally, The India market would display a CAGR of 11.7% during (2023-2030).
Based on Product, the market is segmented into Pumps (Tethered, Patch, and Others), and Consumables. Based on Disease Indication, the market is segmented into Type 1 Diabetes, and Type 2 Diabetes. Based on Distribution Channel, the market is segmented into Retail & Online Pharmacies, and Hospital Pharmacy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, F. Hoffmann-La Roche Ltd., Tandem Diabetes Care, Inc., Insulet Corporation, Ypsomed AG, Aetna, Inc. (CVS Pharmacy, Inc.), SOOIL Developments Co., Ltd, Diabeloop SA, Jiangsu Delfu Medical Device Co.,Ltd, and APEX Medical Corporation
One of the most dynamic areas of healthcare is the care for people with diabetes, which is undergoing several changes. The technique for continuously delivering subcutaneous insulin is one of the cutting-edge technologies. The market is altering how people with diabetes are treated and managed. Additionally, ongoing technology development is opening up new possibilities for the treatment of diabetes, which is anticipated to lead to a high adoption rate in the coming years. The needs of people with type 1 diabetes are met by the goods that have been introduced to the market. There is very little use of insulin pumps among people with type II diabetes.
New potential for the expansion of the market has been created by the boom in published studies concerning the closed-loop system with insulin pumps in the management of diabetes. In the near future, several hybrid systems related to insulin delivery are anticipated to become commercially available. Numerous systems are anticipated to come along with those already on the market.
The WHO reports that China's population is growing older at one of the quickest rates in the countries. By 2040, 28% of China's population is anticipated to be older than 60 due to increased life expectancy and declining birth rates. The aging population is predicted to be more prone to developing a range of illnesses; therefore, it is expected that the prevalence of diseases like cancer, diabetes, and others will increase along with it. Due to all of these considerations, market players operating in the regional nations should have significant growth prospects.
The China market dominated the Asia Pacific Insulin Pump Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $670.8 million by 2030. The Japan market is poised to grow at a CAGR of 10.3% during (2023-2030). Additionally, The India market would display a CAGR of 11.7% during (2023-2030).
Based on Product, the market is segmented into Pumps (Tethered, Patch, and Others), and Consumables. Based on Disease Indication, the market is segmented into Type 1 Diabetes, and Type 2 Diabetes. Based on Distribution Channel, the market is segmented into Retail & Online Pharmacies, and Hospital Pharmacy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, F. Hoffmann-La Roche Ltd., Tandem Diabetes Care, Inc., Insulet Corporation, Ypsomed AG, Aetna, Inc. (CVS Pharmacy, Inc.), SOOIL Developments Co., Ltd, Diabeloop SA, Jiangsu Delfu Medical Device Co.,Ltd, and APEX Medical Corporation
Scope of the Study
By Product
- Pumps
- Pumps
- Consumables
- Consumables
By Disease Indication
- Type 1 Diabetes
- Type 2 Diabetes
By Distribution Channel
- Retail & Online Pharmacies
- Hospital Pharmacy
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- F. Hoffmann-La Roche Ltd.
- Tandem Diabetes Care, Inc.
- Insulet Corporation
- Ypsomed AG
- Aetna, Inc. (CVS Pharmacy, Inc.)
- SOOIL Developments Co., Ltd
- Diabeloop SA
- Jiangsu Delfu Medical Device Co.,Ltd
- APEX Medical Corporation
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Insulin Pump Market by Product
Chapter 5. Asia Pacific Insulin Pump Market by Disease Indication
Chapter 6. Asia Pacific Insulin Pump Market by Distribution Channel
Chapter 7. Asia Pacific Insulin Pump Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Medtronic PLC
- F. Hoffmann-La Roche Ltd.
- Tandem Diabetes Care, Inc.
- Insulet Corporation
- Ypsomed AG
- Aetna, Inc. (CVS Pharmacy, Inc.)
- SOOIL Developments Co., Ltd
- Diabeloop SA
- Jiangsu Delfu Medical Device Co.,Ltd
- APEX Medical Corporation
Methodology
LOADING...
![Global Insulin Delivery Devices Market by Type (Insulin Pens [Reusable, Disposable], Insulin Pumps (Tethered, Tubeless), Insulin Syringes, Insulin Pen Needles (Standard, Safety)), End User (Hospitals & Clinics, Patients/Homecare) - Forecast to 2028 - Product Image](http://www.researchandmarkets.com/product_images/12534/12534941_60px_jpg/global_insulin_delivery_devices_market.jpg)
